| Added by | celine.gongora |
|---|---|
| Group name | EquipeCG |
| Item Type | Journal Article |
| Title | Radium 223 dichloride for prostate cancer treatment |
| Creator | Deshayes et al. |
| Author | Emmanuel Deshayes |
| Author | Mathieu Roumiguie |
| Author | Constance Thibault |
| Author | Philippe Beuzeboc |
| Author | Florent Cachin |
| Author | Christophe Hennequin |
| Author | Damien Huglo |
| Author | François Rozet |
| Author | Diana Kassab-Chahmi |
| Author | Xavier Rebillard |
| Author | Nadine Houédé |
| Abstract | Prostate cancer is the most common malignant disease in men. Several therapeutic agents have been approved during the last 10 years. Among them, radium-223 dichloride (Xofigo®) is a radioactive isotope that induces irreversible DNA double-strand breaks and consequently tumor cell death. Radium-223 dichloride is a calcium-mimetic agent that specifically targets bone lesions. Radium-223 dichloride has been approved for the treatment of metastatic castration-resistant prostate cancer with symptomatic bone metastases, without known visceral metastases. In this review, first we summarize the interplay between prostate tumor cells and bone microenvironment; then, we discuss radium-223 dichloride mechanism of action and present the results of the available clinical trials and future developments for this new drug. |
| Publication | Drug Design, Development and Therapy |
| Volume | 11 |
| Pages | 2643-2651 |
| Date | 2017 |
| Journal Abbr | Drug Des Devel Ther |
| Language | eng |
| DOI | 10.2147/DDDT.S122417 |
| ISSN | 1177-8881 |
| Library Catalog | PubMed |
| Extra | 00000 PMID: 28919714 PMCID: PMC5593411 |
| Tags | agents, Animals, Antineoplastic Agents, bone metastasis, Bone Neoplasms, development, DNA Breaks, Double-Stranded, drug, Humans, last, Male, mCRPC, mechanism, Prostatic Neoplasms, Castration-Resistant, Radioisotopes, Radium, Tumor Microenvironment |
| Date Added | 2019/10/10 - 10:48:39 |
| Date Modified | 2019/10/24 - 15:56:10 |
| Notes and Attachments | PubMed entry (Attachment) Texte intégral (Attachment) |
Institut de Recherche en Cancérologie de
